News

Fierce Biotech2d
Vir's 'functional cure' candidate for hepatitis B misses mark in phase 2
Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...
Medical Xpress19d
Childhood hepatitis B treatment linked to higher odds of long-term virus control
Functional cure, defined as durable hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA titers below the lower limit of detection (LLOD), is associated with better clinical ...
Business Wire26d
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
the primary source of hepatitis B surface antigen (HBsAg) in late-stage disease. Current treatments for patients with HBV infection include agents that result in long-term viral suppression as ...
The Lancet1mon
Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field
HBV=hepatitis B virus. HBVDR=HBV drug resistance ... RAMs in reverse transcriptase can also lead to changes in the overlapping surface antigen (HBsAg), potentially affecting vaccine efficacy. These ...
Frontiers1y
Antibody response and safety of inactivated SARS-CoV-2 vaccines in chronic hepatitis B patients with and without cirrhosis
Conclusion: Cirrhotic CHB patients had lower antibody titers to inactivated SARS-CoV ... The inclusion criteria were as follows: a) over 18 years of age; b) were positive for hepatitis B surface ...
Frontiers5y
NF-κB-Dependent IFIT3 Induction by HBx Promotes Hepatitis B Virus Replication
Therapeutic administration of type I IFN (IFN-I) is a common treatment option for individuals suffering from hepatitis B virus (HBV) infection ... IFIT1 and p65 were purchased from CST (#14769, # 8242 ...